{"title":"回到治疗模式的基础","authors":"","doi":"10.1038/d41573-025-00072-4","DOIUrl":null,"url":null,"abstract":"Andy Plump, Takeda’s head of R&D, discusses the company’s evolving pipeline, therapeutic modalities, and upheaval in biotech, the NIH and the FDA.","PeriodicalId":18847,"journal":{"name":"Nature Reviews Drug Discovery","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Back to therapeutic modality basics\",\"authors\":\"\",\"doi\":\"10.1038/d41573-025-00072-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Andy Plump, Takeda’s head of R&D, discusses the company’s evolving pipeline, therapeutic modalities, and upheaval in biotech, the NIH and the FDA.\",\"PeriodicalId\":18847,\"journal\":{\"name\":\"Nature Reviews Drug Discovery\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Drug Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1038/d41573-025-00072-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/d41573-025-00072-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
